Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BENTHIC BIO INC. maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This pending matter is located in 1 distinct art unit, indicating a concentrated area of technical review for the company's current filings. The prosecution involves 1 distinct examiner, which centralizes the communication between the applicant and the patent office. This suggests that the company's current intellectual property focus is limited to a specific biological or pharmaceutical application.
The busiest examiner, CAIN, JENNIFER LYNN, is responsible for 1 pending office action. This examiner handles the only pending action currently active for the portfolio. With the single examiner and 1 distinct art unit involved, the prosecution environment is highly focused, as all current patent office feedback is contained within a single pending matter. The outcome of the company's current prosecution efforts depends on satisfying the specific criteria established by CAIN, JENNIFER LYNN.
The current prosecution load is focused and manageable. Because the portfolio involves only the single art unit, there is no need to coordinate across different technical groups or manage multiple examiner relationships. This concentration within the Biotechnology & Pharmaceuticals area allows the company to focus its resources on resolving the 1 outstanding office action in an efficient and targeted manner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266396 | COMPOSITION COMPRISING SEA CUCUMBER GENITAL GLAND EXTRACT, COMPOUND DERIVED FROM SEA CUCUMBER OVARY EXTRACT, AND USE THEREOF | CAIN, JENNIFER LYNN | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266396 | COMPOSITION COMPRISING SEA CUCUMBER GENITAL GLAND EXTRACT, COMPOUND DERIVED FROM SEA CUCUMBER OVARY EXTRACT, AND USE THEREOF | CAIN, JENNIFER LYNN | 12d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266396 | COMPOSITION COMPRISING SEA CUCUMBER GENITAL GLAND EXTRACT, COMPOUND DERIVED FROM SEA CUCUMBER OVARY EXTRACT, AND USE THEREOF | CAIN, JENNIFER LYNN | 1655 | §101§102§103 | Non-Final OA | 12d | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial